Literature DB >> 15215246

Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).

Vadim Budagian1, Elena Bulanova, Zane Orinska, Andreas Ludwig, Stefan Rose-John, Paul Saftig, Ernest C Borden, Silvia Bulfone-Paus.   

Abstract

This study shows that the high affinity alpha-chain of the interleukin (IL)-15 receptor exists not only in membrane-anchored but also in soluble form. Soluble IL-15Ralpha (sIL-15Ralpha) can be detected in mouse sera and cell-conditioned media by enzyme-linked immunosorbent assay and by immunoprecipitation and Western blotting. This protein has a molecular mass of about 30 kDa because of the presence of a single N-glycosylation site, which is reduced to 26 kDa after N-glycosidase treatment. Transmembrane IL-15Ralpha is constitutively converted into its soluble form by proteolytic cleavage that involves tumor necrosis factor-alpha-converting enzyme (TACE), and this process is further enhanced by phorbol 12-myristate 13-acetate (PMA) stimulation. The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective. Overexpression of TACE but not ADAM10 in COS-7 cells enhanced the constitutive and PMA-inducible cleavage of IL-15Ralpha. Moreover, murine fibroblasts deficient in TACE but not ADAM10 expression exhibited a significant reduction in the spontaneous and inducible IL-15Ralpha shedding, whereas a reconstitution of TACE in these cells restored the release of sIL-15Ralpha, thereby suggesting that TACE-mediated proteolysis may represent a major mechanism for sIL-15Ralpha generation in mice. The existence of natural sIL-15Ralpha offers novel insights into the complex biology of IL-15 and envisages a new level for therapeutic intervention. Copyright 2004 American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215246     DOI: 10.1074/jbc.M404125200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  ADAM17 regulates TNFα production by placental trophoblasts.

Authors:  R Ma; Y Gu; L J Groome; Y Wang
Journal:  Placenta       Date:  2011-10-20       Impact factor: 3.481

3.  The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.

Authors:  Zheng Wu; Hai-Hui Xue; Jérôme Bernard; Rong Zeng; Dmitry Issakov; Julie Bollenbacher-Reilley; Igor M Belyakov; Sangkon Oh; Jay A Berzofsky; Warren J Leonard
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

Review 4.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

5.  Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles.

Authors:  Emidio E Pistilli; Sasha Bogdanovich; Fleur Garton; Nan Yang; Jason P Gulbin; Jennifer D Conner; Barbara G Anderson; LeBris S Quinn; Kathryn North; Rexford S Ahima; Tejvir S Khurana
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

Review 6.  Trans-presentation: a novel mechanism regulating IL-15 delivery and responses.

Authors:  Spencer W Stonier; Kimberly S Schluns
Journal:  Immunol Lett       Date:  2009-10-07       Impact factor: 3.685

7.  TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis.

Authors:  Manuel Comabella; Cristina Romera; Montse Camiña; Hector Perkal; María A Moro; Juan C Leza; Ignacio Lizasoain; Mireia Castillo; Xavier Montalban
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

8.  How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha.

Authors:  Erwin H Duitman; Zane Orinska; Elena Bulanova; Ralf Paus; Silvia Bulfone-Paus
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

9.  Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Authors:  Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-13       Impact factor: 5.742

Review 10.  Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.

Authors:  Ling Zhang; Rolf Postina; Yingqun Wang
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.